Endobronchial Ultrasound Biopsy Market Share | Industry Report, 2026-2034
REPORT DETAILS
Endobronchial Ultrasound Biopsy Market Summary
The global endobronchial ultrasound biopsy market size was valued at USD 757.29 million in 2025 and is expected to register a CAGR of 4.92% during 2026–2034. Growing preference for minimally invasive procedures drives market demand as patients and physicians favor less invasive techniques due to shorter recovery times, reduced complications, and lower costs compared to open surgeries.
Market Statistics
Key Takeaways
- North America held the largest share of 39.0% in 2025. This is due to the region’s robust healthcare infrastructure and high diagnostic awareness.
- Asia Pacific is projected to register the highest CAGR of 6.25%. The regional market growth is driven by the rising incidence of lung cancer and rapid healthcare infrastructure development.
- The EBUS scopes segment held the largest share of 38.0% in 2025. The segment’s leading position is owing to its indispensable function in real-time navigation and tissue sampling for thoracic diagnostics.
- The ambulatory surgical centers segment is expected to witness the highest CAGR of 5.86%. Increasing procedural volumes and favorable reimbursement models contribute to the segment’s robust growth.
- The EBUS-Transbronchial Needle Aspiration (EBUS-TBNA) segment led with a 78.0% share in 2025. EBUS-TBNA is the internationally recommended first-line procedure for mediastinal lymph node staging.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- The increasing prevalence of chronic respiratory diseases and lung cancer has led to a high demand for endobronchial ultrasound biopsy.
- Technological advancements in biopsy systems and imaging are boosting the adoption of EBUS biopsy techniques across hospitals and diagnostic centers.
- Government-led public health awareness initiatives aimed at early-stage cancer detection are presenting market opportunities.
- The market may face challenges due to a shortage of skilled pulmonologists.
AI Impact on Endobronchial Ultrasound Biopsy Market
- AI technology helps improve biopsy processes in EBUS due to improved image interpretation and detection of any abnormalities.
- AI assists in early and precise detection of pulmonary diseases and cancers through image interpretation.
- The process becomes much easier and less burdensome due to automated workflow and analysis processes.
- AI helps with patient planning and monitoring through its predictive analysis technology.
What is Endobronchial Ultrasound Biopsy?
Endobronchial ultrasound biopsy refers to the segment of the medical device and diagnostic that involves the use of endobronchial ultrasound (EBUS) technology combined with biopsy procedures for the diagnosis and staging of lung cancer, lymph node diseases, and other pulmonary conditions. EBUS biopsy allows real-time imaging and guided sampling of tissues within or adjacent to the airways, offering a minimally invasive surgery alternative to traditional surgical biopsies.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
Expansion of educational programs and specialized training in interventional pulmonology boosts the utilization of EBUS-guided biopsies. Moreover, public health campaigns promoting early detection of lung cancer increase screening and diagnostic activities, including the use of EBUS biopsy. The expansion of healthcare infrastructure in emerging sectors, such as improved access to advanced diagnostic facilities in developing regions, fuels overall growth by enhancing early disease detection, improving patient outcomes, and increasing the efficiency of medical services.
Convex Probe vs Radial Probe EBUS
| Criteria | Convex Probe EBUS | Radial Probe EBUS |
| Main Purpose | Allows real-time needle guidance during biopsies | Used mainly for visualizing peripheral lung lesions |
| Ultrasound Imaging | Performs linear ultrasound imaging with real-time biopsy capability | Performs 360 degree radial ultrasound imaging for lesion localization |
| Biopsy Guidance | Guides needle aspiration using real time imaging | Cannot guide real time needle aspiration |
| Common Uses | Lung cancer staging and mediastinal lymph node sampling | Diagnosis and characterization of peripheral lung lesions |
| Procedure Accuracy | Highly accurate when it comes to targeted sampling | Enhances localization accuracy of lesions that are hard to access |
| Clinical Usage | Used widely in thoracic oncology and staging of cancer | Used widely in pulmonary lesion detection |
| Diagnostic Use | Takes lead in minimally invasive mediastinal biopsies | Helps detect peripheral abnormalities |
Market Dynamics
Increasing Prevalence of Lung Cancer and Chronic Respiratory Diseases
Increasing prevalence of lung cancer and chronic respiratory diseases is significantly contributing to the overall growth. Rising global incidence of lung cancer, driven by factors such as tobacco use, industrial pollution, and aging populations, has intensified the need for precise, early-stage diagnostic tools. EBUS biopsy offers a minimally invasive alternative to traditional diagnostic procedures, enabling accurate sampling of mediastinal and hilar lymph nodes without the risks associated with surgical methods. Healthcare systems are prioritizing early diagnosis to improve treatment outcomes and reduce overall cancer burden, which further elevates the demand for EBUS technology. The increasing burden of chronic respiratory diseases such as COPD and tuberculosis also supports the widespread adoption of EBUS-guided diagnostics in clinical practice.
Technological Advancements in Imaging and Biopsy Systems
Technological advancements in imaging and biopsy systems are accelerating the adoption of EBUS biopsy techniques across diagnostic centers and hospitals. Recent innovations in ultrasound bronchoscope design, such as enhanced image resolution and greater maneuverability, have significantly improved the precision of transbronchial needle aspiration. The development of real-time navigation systems, elastography, and miniaturized biopsy tools allows clinicians to access difficult-to-reach lesions while maintaining procedural safety. Integration of artificial intelligence and machine learning for image interpretation is further refining diagnostic confidence. These continuous improvements are improving clinical outcomes and also streamlining procedures, reducing patient recovery time, and lowering overall healthcare costs. Robust R&D investments from medical device manufacturers are further fueling the evolution of EBUS biopsy systems, making them indispensable in modern thoracic oncology workflows.
Integration with Pulmonary and Oncology Healthcare Systems
EBUS biopsy techniques have now become an integral part of modern pulmonary and oncology healthcare settings, aimed at enhancing diagnostic efficiency and ensuring effective collaboration among healthcare professionals involved in the process. Current EBUS biopsy technologies allow the exchange of imaging information, biopsy results, and clinical data via connections to hospital imaging systems, pathology labs, oncology departments, and EMR platforms. Such integration will help achieve more precise staging of lung cancers, accelerate the treatment planning process, document procedures effectively, and ensure higher continuity of care for patients with thoracic and respiratory cancers.
Source: Polaris Market Research Analysis
Segment Insights
Market Assessment by Product
The endobronchial ultrasound biopsy market segmentation, based on product, includes EBUS scopes, EBUS needles, ultrasound processors & imaging systems, and accessories. In 2025, the EBUS scopes segment held the largest share of 38.0% owing to its indispensable function in real-time navigation and tissue sampling for thoracic diagnostics. EBUS bronchoscopes integrate ultrasound transducers within the bronchoscope tip, enabling visualization of peribronchial structures that were previously inaccessible via conventional bronchoscopy. Increasing clinical preference for minimally invasive approaches to diagnose lung cancer, mediastinal lymphadenopathy, and granulomatous diseases has driven demand for high-performance EBUS scopes. Surgeons and pulmonologists rely on these instruments to achieve greater procedural accuracy while avoiding surgical interventions such as mediastinoscopy. Growing training programs and procedural standardization have further facilitated the incorporation of EBUS scopes in routine pulmonary diagnostic workflows. Rapid technological enhancements, such as high-definition imaging and improved articulation, have also elevated the utility of these devices, solidifying their dominant position in the product landscape.
Market Evaluation by End Use
The endobronchial ultrasound biopsy market segmentation, based on end use, includes hospitals, ambulatory surgical centers (ASCs), and specialty clinics. The ambulatory surgical center segment is expected to witness the highest 5.86% CAGR during the forecast period due to increasing procedural volumes, cost efficiency, and favorable reimbursement models. EBUS-guided procedures are being widely adopted in outpatient settings due to shorter patient recovery times and reduced hospital stays. Rising preference among patients and providers for day-care diagnostics that avoid the complexity of inpatient admissions has significantly strengthened the role of ASCs in pulmonary diagnostics. Advanced infrastructure, availability of skilled pulmonologists, and the adoption of compact, mobile EBUS systems have further optimized diagnostic turnaround in ASCs. Operational flexibility, lower overhead costs, and integration of streamlined diagnostic pathways are collectively contributing to segment growth across high-income and emerging healthcare sector.
Source: Polaris Market Research Analysis
Regional Analysis
By region, the study provides insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, the North America endobronchial ultrasound (EBUS) biopsy market held the largest share of 39.0% due to the region’s robust healthcare infrastructure, high diagnostic awareness, and significant lung cancer burden. Accelerated adoption of advanced minimally invasive diagnostic tools, supported by well-defined reimbursement frameworks, has positioned EBUS biopsy as a frontline procedure for mediastinal and hilar lymph node evaluation. Major academic and tertiary care institutions continue to integrate EBUS into standard diagnostic algorithms for suspected malignancies and staging of non-small cell lung cancer (NSCLC). Substantial product launches and investments in pulmonology-focused research, alongside increased training in interventional pulmonology, have further supported procedural volumes. Widespread availability of technologically sophisticated EBUS equipment and ancillary imaging systems, coupled with stringent clinical guidelines endorsing EBUS over conventional invasive methods, has enhanced regional procedure uptake. Continuous innovation, including real-time elastography and robotic bronchoscopy integrations, also contributes to sustained leadership in North America.
The Asia Pacific endobronchial ultrasound biopsy market is projected to register the highest 6.25% CAGR during the forecast period, driven by the rising incidence of lung cancer, rapid healthcare infrastructure development, and expanding access to advanced diagnostic modalities. National screening programs and growing awareness of early-stage cancer diagnosis are accelerating the deployment of EBUS technologies in urban and semi-urban centers. Emerging economies such as China and India are witnessing increased public and private investment in respiratory diagnostics, spurring demand for minimally invasive procedures that can reduce diagnostic delays. Local manufacturing initiatives and regulatory reforms are improving access to cost-effective EBUS systems. The growing pool of trained pulmonologists, combined with strategic partnerships between global technology providers and regional healthcare institutions, is reinforcing procedural capacity across secondary and tertiary hospitals.
Source: Polaris Market Research Analysis
Key Players & Competitive Analysis Report
The competitive landscape of the endobronchial ultrasound biopsy market is marked by aggressive market expansion strategies, fueled by increasing demand for minimally invasive diagnostic modalities in pulmonary care. Industry analysis indicates a surge in strategic alliances, joint ventures, and technology licensing agreements aimed at strengthening product portfolios and expanding geographic presence. Key players are focusing on mergers and acquisitions to consolidate their market positions and accelerate innovation pipelines, particularly in imaging systems, ultrasound devices, and needle design enhancements. Launches of next-generation EBUS platforms featuring advanced imaging technologies such as elastography, Doppler guidance, and robotic navigation demonstrate a clear trend toward precision diagnostics and improved patient outcomes.
Technology advancements in EBUS scopes and real-time visualization systems are redefining clinical workflows, prompting manufacturers to invest in R&D for better ergonomics, resolution, and compatibility with AI in diagnostic tools. Post-merger integration efforts are emphasizing streamlined distribution, enhanced R&D efficiency, and access to global regulatory channels. Additionally, strategic collaborations with specialty clinics and ambulatory surgical centers are expanding procedural adoption in outpatient settings, driving growth in both developed and emerging economies. The market is also witnessing a shift toward bundled service offerings, where device makers partner with institutions to provide training, support, and integrated diagnostic solutions. Furthermore, regulatory compliance and standardization remain central to competitive differentiation, especially amid evolving clinical guidelines for lung cancer staging.
Fujifilm Corporation is involved in creating, selling, and distributing image, information, and document solutions. The three divisions through which the company functions are Imaging Solutions, Information Solutions, and Document Solutions. The imaging solutions business unit deals with electronic imaging, photofinishing equipment, lab services, film processing, color films, color paper, and chemicals. The information solutions cover visual arts, recording media, and medical and life sciences systems. The Document Solutions division offers printers, office supplies, document creation, and outsourcing services.
List of Key Companies
- ACE Medical Devices Pvt. Ltd.
- Boston Scientific Corporation
- Cook Medical
- ENDO-FLEX GmbH
- FUJIFILM Corporation
- Medi-Globe GmbH
- MICRO-TECH (Nanjing) Co., Ltd.
- MTW-Endoskopie W. Haag KG
- Olympus Corporation
- PENTAX Medical
Industry Developments
- May 2026: FUJIFILM Healthcare Americas Corporation announced the launch of the EB-710US Ultrasound Bronchoscope. The company stated that it’s a next-gen EBUS solution created to streamline workflow and improve imaging performance for pulmonologists and healthcare systems. (source: fujifilm.com)
- February 2026: FUJIFILM Healthcare Europe GmbH announced a distribution partnership with Lys Medical. According to FUJIFILM, the collaboration underscores its commitment to supporting the European Pulmonology market with the most advanced bronchoscopy tools. (source: fujifilm.com)
Endobronchial Ultrasound Biopsy Market Segmentation
By Product Outlook (Revenue, USD Million, 2021–2034)
- EBUS Scopes
- EBUS Needles
- Ultrasound Processors & Imaging Systems
- Accessories
By Procedure Outlook (Revenue, USD Million, 2021–2034)
- EBUS-Transbronchial Needle Aspiration (EBUS-TBNA)
- EBUS-Guided Biopsy
By End Use Outlook (Revenue, USD Million, 2021–2034)
- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Specialty Clinics
By Regional Outlook (Revenue, USD Million, 2021–2034)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Endobronchial Ultrasound Biopsy Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 757.29 million |
| Market Size Value in 2026 | USD 793.92 million |
| Revenue Forecast by 2034 | USD 1,166.59 million |
| CAGR | 4.92% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Million and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Endobronchial Ultrasound Biopsy Market FAQ's
The global market size was valued at USD 757.29 million in 2025 and is projected to grow to USD 1,166.59 million by 2034.
The global market is projected to register a CAGR of 4.92% during the forecast period.
In 2025, the North America held the largest share of 39.0% in 2025.
A few of the key players in the market are ACE Medical Devices Pvt. Ltd.; Boston Scientific Corporation; Cook Medical; FUJIFILM Corporation; Medi-Globe GmbH; Olympus Corporation; PENTAX Medical; ENDO-FLEX GmbH; MICRO-TECH (Nanjing) Co., Ltd.; MTW-Endoskopie W. Haag KG
In 2025, the EBUS scopes segment held the largest share of 38.0% in 2025.
The ambulatory surgical centers segment is expected to witness the highest CAGR of 5.86%.
Download Sample Report of Endobronchial Ultrasound Biopsy Market Share | Industry Report, 2026-2034
Please fill out the form to request a customized copy of the research report.
